Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German price cuts loom for Novartis' Galvus and Merck's Januvia

This article was originally published in Scrip

Executive Summary

Novartis and Merck could soon have to drop the prices of their DPP-4 inhibitors, vildagliptin and sitagliptin, in Germany if health technology appraisal bodies there remain less than impressed. The products are undergoing the first retrospective review under Germany's tough AMNOG pricing and reimbursement system and IQWiG, the Institute for Quality and Efficiency and Healthcare, has just released the preliminary findings.

Topics

Related Companies

UsernamePublicRestriction

Register

SC021972

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel